Mismatched related donors of hematopoietic SCT (HSCT) for severe aplastic anemia (SAA) present challenges mainly associated with graft failure and GVHD. The greater the HLA disparity, the poorer the OS. About 19 consecutive SAA/very SAA (VSAA) patients who received HSCT from haploidentical family donors in our center are reported in this study, 18/19 pairs had 2-3 loci mismatched. All 19 cases failed to respond to previous therapy and were heavily transfused before transplantation. The conditioning regimen before HSCT included BU, CY and thymoglobulin. The recipients received CsA, mycophenolate mofetil (MMF) and short-term MTX for GVHD prophylaxis. The source of stem cell grafts was a combination of G-CSF-primed BM and G-CSF-mobilized peripheral blood stem cells. All patients achieved 100% donor myeloid engraftment; the median time for myeloid engraftment was 12 days (ranging from 10-29 days) and for platelets was 18 days (ranging from 8-180 days) with a cumulative platelet engraftment incidence of 84.21 ± 10.53%. The cumulative incidence was 42.1 ± 11.3% for grade II-IV acute GVHD and 56.2 ± 12.4% for chronic GVHD. The OS was 64.6 ± 12.4% with a median 746-day (90-1970) follow-up for surviving patients. These limited retrospective analysis data suggest that HLA-haploidentical HSCT for SAA patients without an HLA-identical sibling donor might be feasible. Further research to increase OS by decreasing GVHD while maintaining stable engraftment will be needed in the future.
INTRODUCTION
Allogeneic hematopoietic SCT(allo-HSCT) is the treatment of choice for patients with severe aplastic anemia (SAA) who have an HLA-identical sibling or matched-alternative donor, but the use of partially matched family donors has been unsuccessful because of the high incidence of graft rejection and GVHD. Data from the Seattle and Europe BMT (EBMT) groups indicate that patients with HLA-mismatched related donors have a survival rate that is generally 50% or less 1,2 o20% for two or more locimismatched recipients in an earlier reports. 3 Although progress has been made in haploidentical HSCT, which is now used to perform haploidentical SCT for patients with hematological malignancies, only a few cases of mismatched, related-donor transplants in SAA could been found in the literature, and most of these cases have only one mismatched Ag. [1] [2] [3] In immunoseppressive therapy (IST)-refractory patients, large doses of highly purified CD34 þ -selected hematopoietic stem cells from haploidentical donors after an intensified immunoablative conditioning regimen can result in stable engraftment without increasing GVHD, but there is not enough data to show that better survival is achieved. 4, 5 Reported results of mismatched relative donor transplantation for SAA are somewhat heterogeneous, and most series are limited by the small numbers of patients and the fact that cases may receive different conditioning and GVHD prophylaxis regimens. [1] [2] [3] [4] [5] Information at the level of detail required for decision-making, such as outcome of transplants from a mismatched related donor as upfront or salvage treatment with information on the degree of HLA matching, is lacking. A novel approach to HLA-mismatched/haploidentical blood and marrow transplantation without in vitro T-cell depletion has been developed by Peking University researchers and gives robust recovery and excellent survival rates for the treatment of malignant hematological disease, [6] [7] [8] but it is undetermined if a similar procedure is suitable for patients with SAA. 1, 3 A similar protocol has been used for 19 SAA patients in the past 5 years in our center. To the best of our knowledge, this study is the largest single-center trial in which a fixed protocol was used in SAA patients receiving transplants from haploidentical donors with 2-3 mismatched loci.
SUBJECTS AND METHODS

Study setting and participants
Consecutively acquired SAA patients who underwent HLA-mismatched/ haploidentical allo-HSCT at the Institute of Hematology, Peking University, between 1 January 2006 and 31 March 2011 were enrolled in this study. Patients met the following criteria: (1) diagnosed with SAA or VSAA, as defined by the International Aplastic Anemia Study Group; 9 (2) no response to previous therapy, including CsA þ stanozole/andriol± G-CSF±anti-human thymocyte Ig (ATG)±EPO±glucocorticoid; (3) recipients of multiple transfusions and transfusion dependent at the time of transplant; (4) voluntary participation in HSCT; (5) absence of uncontrolled infections and severe liver, renal, lung and heart diseases; (6) lack of available, HLA-identical, related sibling or unrelated donor; and (7) written informed consent obtained from patients or their guardians and donors. This study was approved by the Institutional Review Board of Peking University.
HLA compatibility was determined by low-resolution DNA techniques for HLA-A and B loci and high-resolution DNA techniques for HLA-DRB1. Patients and their donors were haploidentical; donors were ranked on the basis of HLA match, age (younger preferred), gender (same preferred) and health status (better preferred).
Conditioning regimen
Days of treatment were named sequentially; for instance, the first day of stem cell infusion was designated as 'day 01' and the second day of infusion was 'day 02'. Days before transplant are preceded by ' À ', and days after the last stem cell infusion are preceded by ' þ '. All patients were treated with a regimen that consisted of the following: BU: 3.2 mg/kg intravenously (i.v.) in divided doses daily for 2 days (total dose 6.4 mg/kg) on days À 7 and À 6; CY: 50 mg/kg/day once daily i.v. for 4 consecutive days on days À 5, À 4, À 3 and À 2 (total dose 200 mg/kg); and ATG (rabbit, Sangstat product Lyons, France): 2.5 mg/kg once daily i.v., or ATG (porcine, Bioproduct, Wuhan, China): 20 mg/kg once daily i.v. for 4 consecutive days on day À 5 to À 2 (total dose 10 and 80 mg/kg, respectively).
Stem cell harvest
Donors were treated with rhG-CSF (Filgrastim, Kirin, Japan; 5 mg/kg/day) injected subcutaneously for 5-6 consecutive days from day À 3. On the fourth day of mobilization, BM cells were harvested to achieve a target volume of 10-12 mL/kg of donor weight or a target mononuclear cell (MNC) count of 2-4 Â 10 8 /kg of recipient weight. On the fifth day of mobilization, PBSCs were collected with a COBE Blood Cell Separator (Spectra LRS; COBE BCT Inc., Lakewood, CO, USA) at a rate of 80 mL/min from a total blood volume of 10-12 L. The target MNC from BM and peripheral blood was 6-8 Â 10 8 /kg of recipient weight. An additional collection of PBSCs was required the next day if the cell numbers from the previous 2 days were insufficient. Fresh and unmanipulated BM and PBSCs were infused into the recipient on the day of their collection. In instances of major ABO blood group incompatibility, red blood cells were removed from BM cells by density gradient sedimentation with Hespan (B. Braun Medical Inc., Irvine, CA, USA) according to the manufacturer's instructions. The surface markers of the graft cells were determined by multicolor staining using MoAbs specific for CD34 þ , CD3 þ , CD4 þ and CD8 þ cells, as described by Huang et al. 6, 7 GVHD prophylaxis and treatment All transplant recipients received CsA, MMF and short-term MTX for acute GVHD prophylaxis. The dosage of CsA was 2.5 mg/kg/day i.v., administered in two doses from day À 9 until bowel function returned to normal, at which time patients received oral CsA. Every 12 h, 0.5 g MMF (0.25 g for children) was administered orally from day À 9 to þ 30 and subsequently 0.25 g from days þ 30 to þ 60. MTX was administered at a dose of 15 mg/m 2 i.v. on day þ 1 and 10 mg/m 2 on days þ 3, þ 6 and þ 11. Trough concentration of CsA was monitored using a fluorescence polarization immunoassay, a target trough blood concentration of 200-250 ng/ml was requested till 12 months after HSCT and was gradually tapered thereafter, withdrew CsA completely in next 2-3 months. In cases where GVHD occurred in any organ, CsA was continued and adjusted up to the therapeutic concentration. Acute GVHD was treated as described by Huang et al. [6] [7] [8] in previous paper.
Infection prevention and supportive care
All patients were cared for in a laminar air-flow room and received nonabsorbable oral antibiotics for gastrointestinal decontamination (norfloxacin capsules for adults and gentamycin for children) from day À 9 to myeloid recovery. Recipients received G-CSF (5 mg/kg/day, subcutaneously) from day þ 6 until myeloid recovery. Infection prophylaxis around the transplant period has been described by Huang et al. [6] [7] [8] in our previous paper. Patients were monitored weekly for CMV DNA (realtime PCR) and EBV-DNA after HSCT. CMV antigenemia patients received preemptive ganciclovir (DHPG) or foscarnet therapy. Human Ig (400 mg/kg) from volunteer healthy donors was administered i.v. on days þ 1, þ 11, þ 21 and þ 31.
Definitions and assessment of engraftment
Myeloid engraftment was defined as the first of three consecutive days with an ANC X0.5 Â 10 9 /L, and platelet engraftment was defined as the day the platelet count met or exceeded 20 Â 10 9 /L without transfusion for a week. Hematopoietic chimerism was evaluated by FISH for sexmismatched patient-donor pairs and by PCR amplification of STRs for sex-matched pairs using peripheral blood samples from the donor and the recipient. After HSCT, recipient BM samples were drawn monthly for the first 3 months and every 3-6 months for an additional 1-2 years. Complete donor chimerism was defined as the presence of only donor-type hematopoietic cells after allogeneic BMT. T-cell subset of peripheral blood was monitored on þ 1, þ 2, þ 3, þ 6, þ 9 and þ 12 months.
Primary graft failure was defined by the absence of hematological recovery in patients surviving X21 days after transplantation, and late rejection was defined as graft loss after initial graft function, that is, complete or partial recovery of hematopoiesis of donor origin followed by recurrent pancytopenia with a markedly hypocellular BM in the absence of moderate to severe acute GVHD. 10, 11 The incidence and severity of GVHD were based on a NIH consensus conference to determine GVHD grade. 12 Patients were evaluated for cGVHD if they survived for at least 100 days after HSCT.
Statistics
The primary endpoint of the study was the engraftment rate after transplantation. Secondary endpoints included OS, TRM and incidence and severity of GVHD. Platelet engraftment was calculated to accommodate corresponding competing risk. Engraftment and GVHD were analyzed as time-dependent variables; TRM and OS were estimated using the Kaplan-Meier method. The date of the last follow-up for all surviving patients was 30 June 2011. Statistical software packages (SPSS 16.0, SPSS Inc., 1989-2007 and R Software, Boston, MA, USA) were used for the analyses.
RESULTS
Patients and their donors
A total of 19 patients was enrolled in the study. The patients' median age was 19 years (ranging from 5 to 33). Five of these patients were VSAA cases. Four (21.05%) cases had failed to respond to previous IST treatment, including at least one course of ATG/CsA before BMT; the remaining patients had failed to respond to CsA±stanozolol or testosterone ± steroids. Data are shown in Table 1 .
All donors tolerated the procedures well, and no severe side effects occurred during BM harvest and leukapheresis. As part of the conditioning regimen, 2 patients received porcine ATG and 17 patients received rabbit ATG. The median MNC and CD34 þ counts for both BM and PBSC are shown in Table 2 . Engraftment Myeloid recovery and full donor chimerism were both achieved in 19 patients after transplantation without primary graft failure; the median time for myeloid engraftment was 12 days (range 10-29). All but two patients sustained complete stable donor chimerism. The two exceptions (2/19 or 10.5%) had transient engraftment but developed late graft failure. Of these patients, one patient developed late graft failure on day þ 67 and was treated with fludarabine and CD25 MoAb followed by an infusion of PBSCs from the original donor on day þ 99. The patient recovered 12 days after infusion, but died of refractory CMV disease on day þ 208. The other patient developed late graft failure on day þ 120 after suffering severe GVHD and several weeks of CMV antigenemia. This patient had received a G-CSF booster without HSC infusion and nonengraftment continued before he died of infection on day þ 145. Three patients did not achieve platelet engraftment before death ( þ 60, þ 126 and þ 208 days, respectively). The cumulative incidence of platelet engraftment was 84.21 ± 10.53% with a median of 18 days (range 8-180).
GVHD
Acute GVHD. Of the 19 patients, 9 (47.4%) cases had no aGVHD, 2 (10.5%) cases had grade I, 4 (21.05%) cases had grade II, 3 (15.8%) cases had grade III and 1 (5.26%) case had grade IV aGVHD (as shown in Table 3 ). At 100 days after transplantation, the cumulative incidence of aGVHD grades II-IV was 42.1±11.3% and that of grades III-IV was 21.1 ± 9.4% (Figure 1a) .
Chronic GVHD. Of the 16 patients who survived for more than 100 days after transplantation, 9 (56.25%) developed cGVHD. Of these patients, 7 (43.75%) showed mild cGVHD, 1 (6.25%) showed moderate cGVHD and 1 (6.25%) showed severe cGVHD (as shown in Table 3 ). The cumulative incidence of cGVHD and moderate/ severe cGVHD was 56.2 ± 12.4 and 12.5% ± 8.3%, respectively (Figure 1b) . Of the 12 patients surviving longer than 100 days, 7 patients without cGVHD and 4 patients with mild cGVHD had tapered off CsA at scheduled time, one patient with successfully controlled moderate cGVHD will taper CsA from þ 12 months after HSCT. Four patients who have cGVHD died, one patient died of severe cGVHD on day 126, one patient with mild cGVHD died from infection on the day 505 after withdrawal of CsA, two patients with mild cGVHD died from late graft failure on the day 187 and 208 before CsA should be tapered.
Transplantation-related toxicity All patients received the conditioning regimen on schedule without encountering any significant bowel, renal or liver toxicity. A total of 17 patients was monitored for T-cell subset recovery in the blood. Data are shown in Table 4 .
OS and treatment-related mortality Through 30 June 2011, six patients died; the TRM at þ 100 day, þ 1 year and þ 2 years was 10.5 ± 7.0, 27.3 ± 10.4 and 35.4 ± 12%, respectively. The causes of TRM include GVHD in two cases, infection in two cases and graft failure in two cases. A total of 13 patients have survived at a median follow-up of 746 days (range 90-1970) with an OS rate of 64.5% (Figure 2) . All of the 13 surviving patients achieved a hematologic CR.
DISCUSSION
Compared with malignant disease, mismatched-related donor HSCT for SAA involves distinct challenges mainly associated with high graft failure and high GVHD. Graft failure after allo-BMT for SAA has been strongly associated with higher degrees of histoincompatibility and allosensitization to histocompatibility antigens through previous blood product transfusions. [1] [2] [3] Previously transfused patients have lower OS compared with untransfused patients, primarily because of complications due to graft failure. [13] [14] [15] In an early report, Seattle found that in transplants from related donors mismatched at one or more loci with CY ± ATG conditioning, the incidence of graft failure was 71%, grade II-IV aGVHD was 16% and cGVHD was 100%, with a 1 year OS of 0% being observed (n ¼ 15). 1 Various attempts have been made over the years to improve OS by reducing graft failure and GVHD, but there are few related reports and most data come from very small patients number. [16] [17] [18] [19] Chan and EBMT report successful mismatched HSCT with a fludarabine-based conditioning regimen (plus CY and ATG) for SAA patients, their data are from only 3-5 cases with only one Ag-mismatched case. 16, 17 Various doses of irradiation were added to the conditioning regimen to achieve sustained engraftment. 2, 19 Wagner et al. describe 16 patients receiving HSCT from donors with 1-3 mismatched HLA loci after conditioning with CY/TBI (200 cGy/d Â 6 d); the incidence of graft failure decreased to 14%, but there was a high incidence (78%) of stage II-IV aGVHD. 2 Vassiliou et al. 18 report improved outcomes of alternative donor BMT in children with SAA using a conditioning regimen containing low-dose TBI (3 Gy), CY and alemtuzumab, but there is only one haploidentical donor included in their report. Tzeng et al. 19 report that six transfused patients received a novel conditioning regimen of CY 200 mg/kg and TBI 800 cGy before receiving marrow from HLA-haploidentical family donors. Engraftment was noted in all patients, although only four patients (66.7%) survived. Of the six 
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Abbreviations: ATG ¼ anti-human thymocyte Ig, HSCT ¼ hematopoietic SCT; SAA ¼ severe aplastic anemia; VSAA ¼ very SAA.
patients, four recipient-donor pairs (66%) were mismatched for one HLA locus among the A, B and DR loci. In our study, all 19 patients had received multiple transfusions before HSCT and 95% (18/19) had 2-3 mismatched loci. This group of patients is theoretically in high-risk for graft failure, but in fact, non-patients get primary graft failure. Several unique aspects of our protocol may have helped to facilitate engraftment. These aspects include (1) an intensified conditioning regimen that adds BU to CY þ ATG based on a previous report that the addition of low doses of BU to the standard conditioning regimen in HLAidentical sibling donor HSCT reduces rejection; 20 (2) the combination of G-BM and G-PB grafts work synergistically to enhance engraftment; [21] [22] [23] and (3) the employment of a more potent GVHD prophylactic treatment regimen using CsA, MTX and MMF.
In haploidentical HSCT for patients with SAA, overall mortality remains high and is primarily due to graft failure, GVHD and infectious complications. In contrast, we observed that cumulative incidence of GVHD in this trial is on par with haploidentical HSCT for malignant hematological disease reported previously. [6] [7] [8] However, SAA patients received no additional protection from GVHD compared with patients with other malignant hematological disease. Using an ex vivo T-cell depletion procedure might decrease GVHD, but no better OS has been reported. Woodard et al. have assessed the effectiveness of infusing large numbers of highly purified haploidentical CD34 þ cells after immunoablative conditioning in three patients who had failed intensive immunosuppression. One patient rejected the first infusion, but engrafted after a second infusion from the same donor. This patient died 4 months after HSCT with no evidence of lymphoid reconstitution. Two patients experienced mixed chimerism requiring treatment with antibodies and/or DLI. Both currently survive more than 1 year after transplantation with normal blood counts, 100% donor engraftment, effective lymphoid reconstitution and no chronic GVHD. 4 Passweg et al. report that among 66 cases with 1 locus mismatched relative donor HSCT and 20 cases with 41 mismatched relative donor HSCT, one-third of the cases received purified CD34 þ cells. The reported rates of 100-day graft failure were 21 and 25%, 1-year failure rates were 26 and 25%, aGVHD rates were 35 and 15%, cGVHD rates were 18-19 and 23%, 1-and 3-year OS rates were 49 and 35%, respectively. 5 These data are no better than our results showing the OS was 64.5% with complete hematological recovery in 13/13 (100%) surviving patients. Although the incidence rates of aGVHD and cGVHD were higher in our trial, most cases of cGVHD were mild and well-controlled, the immune function recovered timely (as shown in Table 3 ); therefore, perhaps we found the proper balance between engraftment, GVHD and immune function. Current practice guidelines do not recommend transplantation from an alternative donor as a first-line treatment. These limited data give encouraging results and suggest HLA-mismatched/ haploidentical HSCT without in vitro T-cell depletion might be feasible for SAA/VSAA patients without HLA-identical sibling or unrelated donors as a salvage therapy. In addition, this non-TBI conditioning prevented patients against the side effects of irradiation that affect physical growth, fertility and hormone production, especially in more susceptible pediatric and adolescent age groups. The major limitation of this analysis is that only 4/19 of cases received HSCT as salvage therapy after failure to previous ATG þ CsA, the other patients received HSCT as upfront therapy after failure to CsA-based treatment and had not been evaluated for the effect of ATG before. A total of 2 out of 4 patients survived after receiving HSCT salvage therapy, and 11 out of 15 survived among the other cohort patients, we cannot tell which is better. Before widespread adoption of upfront or salvage treatment for SAA/VSAA patients, these results need to be validated in a larger cohort. Further research to increase OS by decreasing GVHD while maintaining a stable engraftment will be needed in the future. Table 4 . Recovery of T-cell subsets in the blood in SAA patients receiving haploidentical HSCT (n ¼ 17)
T-cell subsets median (range)/months after HSCT Figure 2 . OS of SAA patients after HSCT (n ¼ 19).
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